Literature DB >> 31122569

Drastic Response of Re-challenge of EGFR-TKIs Immediately After Nivolumab Therapy in EGFR-TKI-Resistant Patients.

Kyoichi Kaira1, Hiroshi Kagamu2.   

Abstract

Entities:  

Year:  2019        PMID： 31122569     DOI： 10.1016/j.jtho.2019.02.011

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  4 in total

1.  Effectiveness of EGFR-TKI rechallenge immediately after PD-1 blockade failure.

Authors:  Kyoichi Kaira; Kunihiko Kobayashi; Ayako Shiono; Ou Yamaguchi; Kosuke Hashimoto; Atsuto Mouri; Shun Shinomiya; Yu Miura; Hisao Imai; Hiroshi Kagamu
Journal:  Thorac Cancer       Date:  2021-01-31       Impact factor: 3.500

2.  Case Report: Re-Sensitization to Gefitinib in Lung Adenocarcinoma Harboring EGFR Mutation and High PD-L1 Expression After Immunotherapy Resistance, Which Finally Transform Into Small Cell Carcinoma.

Authors:  Xiaoqian Zhai; Jiewei Liu; Zuoyu Liang; Zhixi Li; Yanyang Liu; Lin Huang; Weiya Wang; Feng Luo
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

3.  Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer.

Authors:  Yosuke Miura; Norimitsu Kasahara; Noriaki Sunaga
Journal:  Transl Cancer Res       Date:  2019-12       Impact factor: 1.241

Review 4.  The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation.

Authors:  Lin Ma; Bowen Diao; Zhaoqin Huang; Bin Wang; Jinming Yu; Xiangjiao Meng
Journal:  Cancer Commun (Lond)       Date:  2021-10-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.